Mary M. Rozenman files SEC Form 4 disclosures for Aimmune Therapeutics, Inc.. They have made 13 open-market trades across 1 company since 2016, most recently 2019-03-01.
CIK 0001631650
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AIMT | 13,878 | $479K |
Shares reported on the most recent Form 4, priced at the 2020-02-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AIMT | SELL | 2018-03-01 | 2018-03-05 | $33.10 | $120K | -10.3% | -17.4% | -11.5% |
| AIMT | SELL | 2018-02-01 | 2018-02-05 | $35.45 | $386K | +9.3% | -1.4% | -10.8% |
| AIMT | SELL | 2018-01-02 | 2018-01-04 | $37.11 | $489K | +2.5% | -4.3% | -19.5% |
| AIMT | SELL | 2017-12-26 | 2017-12-28 | $38.86 | $2.4M | +0.3% | -6.3% | -17.9% |
| AIMT | SELL · 10b5-1 | 2017-12-26 | 2017-12-28 | $38.91 | $381K | +0.3% | -6.3% | -17.9% |
| AIMT | SELL | 2017-09-07 | 2017-09-11 | $22.50 | $675K | +3.0% | +10.2% | +47.2% |
| AIMT | SELL | 2017-07-14 | 2017-07-17 | $21.39 | $121K | -1.9% | -10.1% | +18.5% |
| AIMT | SELL · 10b5-1 | 2017-07-13 | 2017-07-17 | $21.44 | $320K | -1.9% | -10.1% | +18.5% |
| AIMT | SELL | 2017-07-13 | 2017-07-17 | $21.47 | $193K | -1.9% | -10.1% | +18.5% |
| AIMT | SELL | 2017-07-05 | 2017-07-06 | $21.40 | $322K | +4.5% | +1.6% | +26.7% |
| AIMT | SELL | 2017-07-03 | 2017-07-06 | $20.57 | $617K | +4.5% | +1.6% | +26.7% |
| AIMT | SELL | 2017-07-03 | 2017-07-06 | $20.85 | $939K | +4.5% | +1.6% | +26.7% |
| AIMT | SELL | 2016-11-04 | 2016-11-04 | $17.60 | $848K | +42.6% | +24.9% | -1.6% |
| AIMT | SELL | 2016-10-05 | 2016-10-07 | $16.80 | $420K | -0.6% | +16.4% | +31.9% |
| AIMT | SELL | 2016-09-08 | 2016-09-09 | $16.80 | $504K | +5.8% | +11.0% | +50.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.